ProQR Therapeutics N.V. PRQR
1.65
(0.06)
(3.51%)
as of 25 Sep
- Market cap
- $236.1M
- P/E
- 0.0×
Follow PRQR
Insider Buys
alert about insiders buying in the last 12 month
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | — | — | — | 0.00 | 57.44 | 23.90 | 11.15 | 11.82 |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 7.69 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | 117.86 | (11.56) | (28.44) | (23.66) | (15.61) |
P/B ratio |
— | — | — | — | — | 3.84 | 3.56 | 3.76 | 2.38 | 3.81 |
Price to Tangible BV |
— | — | — | — | — | 3.84 | 3.56 | 3.77 | 2.38 | 3.81 |
EV/Sales |
— | — | — | — | — | 0.00 | 35.64 | 6.66 | 3.72 | 6.58 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | — | — | — | (11.19) | (2.10) | 2.01 | (1.93) | (1.98) |
EV/FCF |
— | — | — | — | — | (11.01) | (2.08) | 2.15 | (1.86) | (1.94) |
Quick Ratio |
9.04 | 5.72 | 13.19 | 10.29 | 7.45 | 6.82 | 7.24 | 3.48 | 3.84 | 3.06 |
Current Ratio |
9.24 | 5.95 | 13.28 | 10.43 | 7.77 | 6.94 | 7.32 | 3.54 | 3.95 | 3.09 |
Net Debt/EBITDA |
1.40 | 1.04 | 2.73 | 1.79 | 1.46 | 2.61 | 1.42 | 3.91 | 5.23 | 2.15 |
Debt/Assets |
8.69% | 13.64% | 8.51% | 11.10% | 17.55% | 21.04% | 3.95% | 3.11% | 2.73% | 4.32% |
Debt/Equity |
0.11 | 0.18 | 0.10 | 0.14 | 0.31 | 0.39 | 0.10 | 0.10 | 0.05 | 0.10 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.04 | 0.12 | 0.12 |
Operating CF/Net income |
0.88 | 0.80 | 0.77 | 0.77 | 1.01 | 0.42 | 1.05 | (0.77) | 1.31 | 1.25 |
Capex/Depreciation |
(2.04) | (0.11) | (0.31) | (0.28) | (0.39) | (0.18) | (0.28) | 2.64 | (0.51) | (0.38) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (54.60%) | (95.54%) | (56.62%) | (59.24%) | (62.69%) | (73.43%) | (67.73%) | (53.67%) | (42.73%) | (62.93%) | |
| (47.11%) | (74.42%) | (45.82%) | (48.55%) | (43.52%) | (40.42%) | (32.02%) | (18.46%) | (18.15%) | (30.86%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(66.57%) | (97.91%) | (36.15%) | (53.48%) | (52.72%) | (33.98%) | (43.53%) | (27.12%) | (21.51%) | (52.52%) |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 213.25 | 5,241.94 | 0.00 | 0.00 | 156.04 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 3,118.20% | 1,260.02% | 386.06% | 192.31% | 281.23% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,282.73% | 462.00% | 249.25% | 72.26% | 94.68% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 459.09% | 71.07% | 47.68% | 13.46% | 25.24% |
Graham Net Nets |
— | — | — | — | — | 0.22 | 0.21 | 0.16 | 0.35 | 0.20 |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | — | — | — | (14.36%) | (27.57%) | (18.75%) | (12.83%) | (22.77%) |
Free Cash Flow Yield |
— | — | — | — | — | (6.08%) | (29.85%) | 13.00% | (17.94%) | (28.61%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | 0.09 | 0.24 | 0.17 |
Operating CF per Share |
(1.62) | (1.56) | (0.99) | (1.20) | (1.07) | (0.48) | (1.01) | 0.29 | (0.46) | (0.57) |
Capex per Share |
(0.12) | (0.01) | (0.01) | (0.02) | (0.02) | (0.01) | (0.01) | 0.09 | (0.02) | (0.01) |
Free Cash Flow per Share |
(1.74) | (1.56) | (1.00) | (1.22) | (1.09) | (0.49) | (1.02) | 0.38 | (0.48) | (0.58) |
Cash per Share |
2.81 | 2.14 | 3.66 | 3.06 | 1.73 | 3.46 | 1.39 | 1.59 | 1.88 | 0.99 |
Shareholders Equity per Share |
2.52 | 1.75 | 3.21 | 2.56 | 1.29 | 2.09 | 0.96 | 0.55 | 1.11 | 0.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.52 | 1.75 | 3.21 | 2.56 | 1.29 | 2.09 | 0.96 | 0.55 | 1.11 | 0.53 |
Free Cash Flow |
(40.68) | (39.64) | (34.02) | (49.90) | (54.81) | (31.28) | (72.92) | 30.50 | (40.92) | (60.88) |
Working Capital |
61.20 | 47.55 | 118.34 | 116.11 | 79.64 | 193.89 | 140.50 | 93.93 | 124.38 | 76.58 |
Capital Expenditures |
(2.81) | (0.14) | (0.37) | (0.65) | (1.06) | (0.50) | (0.74) | 7.17 | (1.53) | (1.15) |
Net Current Asset Value |
54.90 | 41.57 | 107.26 | 101.88 | 43.22 | 112.55 | 50.84 | 26.51 | 80.56 | 41.57 |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.31 | 0.17 | (1.02) | 0.08 | 0.06 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (4,551.08%) | (1,612.85%) | (431.67%) | (146.86%) | (265.21%) |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.36 | 0.43 | 0.53 | 0.84 | 0.13 | 0.13 | 0.16 | 0.15 | 0.20 | 0.21 |
Cash ROIC |
(31.91%) | (39.57%) | (14.62%) | (21.21%) | (43.86%) | (12.61%) | (50.85%) | 2.83% | (20.82%) | (44.61%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.67 | 0.14 | 0.00 | 0.00 | 0.52 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | — |
Average Receivables |
1.13 | 1.11 | 1.51 | 1.89 | 1.16 | 0.96 | 31.01 | — | — | 34.39 |
Average Payables |
0.67 | 0.49 | 0.39 | 0.33 | 0.38 | 0.24 | 0.32 | 1.04 | 0.84 | 0.18 |
Average Assets |
91.85 | 66.28 | 95.10 | 130.91 | 122.21 | 180.37 | 214.23 | 164.87 | 165.49 | 154.66 |
Average Common Equity |
79.26 | 51.62 | 76.96 | 107.28 | 84.84 | 99.28 | 101.28 | 56.70 | 70.31 | 75.85 |
Columns are period end dates